fig1

Figure 1. Overall analysis in all patients. (A) Network geometry of OS comparisons among all regimens; edge thickness reflects number of direct comparisons; (B) Forest plot of OS HRs vs. chemotherapy (values < 1 favor the experimental regimen); (C) Heatmap summarizing rank positions across OS, PFS, ORR, and AEs (1 = best; higher numbers = worse); (D) SUCRA-based ranking for OS showing the overall hierarchy of regimens; (E) League table of pairwise OS comparisons reporting HRs (95%CrI) between regimens; cells < 1 favor the row treatment over the column treatment. OS: Overall survival; HRs: hazard ratios; PFS: progression-free survival; ORR: objective response rate; AEs: adverse events; SUCRA: surface under the cumulative ranking curve; CrI: credible interval; ICI+ICI: dual immune checkpoint inhibitor therapy; ICI+Chemo: immune checkpoint inhibitor plus chemotherapy; ICI+ADC: immune checkpoint inhibitor plus antibody–drug conjugate; ICI+PARPi: immune checkpoint inhibitor plus poly(ADP-ribose) polymerase inhibitor; Chemo: platinum-based chemotherapy; Chemo+Chemo: chemotherapy doublets; ICI+TKI: immune checkpoint inhibitor plus tyrosine kinase inhibitor; Chemo+TKI: chemotherapy combined with tyrosine kinase inhibitors; CI: confidence interval; NA: not applicable.